Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases
Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases
复制标题
DOI：
10.1016/j.phrs.2023.106983
复制
发表时间：
2023-11-10
影响因子：
9.3
通讯作者：
Xu，Hao
中科院分区：
文献类型：
--
作者：
Wang，Anlu;Guan，Baoyi;Xu，Hao
心脏代谢病（Cardiometabolic diseases，CMD）是以一系列代谢紊乱和慢性低度炎症为特征的疾病。CMD在全球范围内造成高死亡率和发病率负担。宿主-微生物代谢调节触发metaflammation是一个新兴的研究领域，促进了感知心血管风险的新视角。术语metaflammation表示由称为“代谢相关代谢物”（DAM）的一类新代谢物激活的整个免疫应答级联。这是本次审查首次提出的。我们总结了目前的研究，涵盖了从实验室到床边的DAM方面，以更好地了解在DAM背景下的CMD。我们关注DAM参与CMD的病理生理发展，包括免疫稳态的破坏和慢性炎症触发的损伤导致CMD相关的不良事件，以及针对CMD中DAM代谢的新兴治疗方法。
Cardiometabolic diseases (CMDs) are characterized by a series of metabolic disorders and chronic low-grade inflammation. CMDs contribute to a high burden of mortality and morbidity worldwide. Host-microbial metabolic regulation that triggers metaflammation is an emerging field of study that promotes a new perspective for perceiving cardiovascular risks. The term metaflammation denotes the entire cascade of immune responses activated by a new class of metabolites known as “danger-associated metabolites” (DAMs). It is being proposed by the present review for the first time. We summarize current studies covering bench to bedside aspects of DAMs to better understand CMDs in the context of DAMs. We have focused on the involvement of DAMs in the pathophysiological development of CMDs, including the disruption of immune homeostasis and chronic inflammation–triggered damage leading to CMD-related adverse events, as well as emerging therapeutic approaches for targeting DAM metabolism in CMDs.